Beyond the Algorithm: What 10 Fringe Stocks Tell Us About the MarketGlobal Report·Jul 28 at 04:13 AMGSUN+5.73%PSX+0.51%
Climb Bio (NASDAQ:CLYM) Trading 10.9% Higher After Analyst UpgradeMarket Beat·Jul 27 at 09:20 AMCLYM-1.49%
Wedbush Forecasts Strong Price Appreciation for Climb Bio (NASDAQ:CLYM) StockMarket Beat·Jul 27 at 08:18 AMCLYM-1.49%
Climb Bio: Unique APRIL Inhibitor Profile Supports Buy Rating and Unchanged $20 Price TargetTip Ranks·Jul 21 at 02:01 PMCLYM-1.49%
5 Biotech Stocks That Delivered 100% To 300% Gains: Did Your Winning Trades Offset Portfolio Losses?rttnews·Jul 6 at 04:55 AMURGN-6.94%CLYM-1.49%
Climb Bio director Breanna Maurine Celebi files initial beneficial ownership statementPUBT·Jul 1 at 03:25 PMCLYM-1.49%
Climb Bio reports translational model, Phase 1 safety and dose data for CLYM116TradingView·Jun 5 at 06:23 AMCLYM-1.49%
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development | CLYM Stock NewsStockTitan·Jun 4 at 10:00 PMCLYM-1.49%
